LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

12.59 -4.04

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.37

Max

13.12

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	4.989 49.8
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+52.32% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.3B
Ankstesnė atidarymo kaina	16.63
Ankstesnė uždarymo kaina	12.59

Naujienos nuotaikos

By Acuity

50%

175 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

14.24 / 14.78 Palaikymas ir pasipriešinimas

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-11 22:15; UTC

Įsigijimai, susijungimai, perėmimai

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

2026-05-11 23:46; UTC

Rinkos pokalbiai

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

2026-05-11 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on AI Enthusiasm -- Market Talk

2026-05-11 23:33; UTC

Rinkos pokalbiai

Gold Rises on Possible Position Adjustments -- Market Talk

2026-05-11 22:37; UTC

Rinkos pokalbiai

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

2026-05-11 22:32; UTC

Uždarbis

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

2026-05-11 22:02; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

2026-05-11 21:49; UTC

Uždarbis

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

2026-05-11 21:42; UTC

Rinkos pokalbiai

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

2026-05-11 21:31; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

2026-05-11 21:23; UTC

Įsigijimai, susijungimai, perėmimai

CSG Systems Sale to NEC Gets CFIUS Clearance

2026-05-11 21:12; UTC

Uždarbis

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

2026-05-11 21:12; UTC

Uždarbis

Ovintiv 1Q Loss/Shr $2.35 >OVV

2026-05-11 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-11 20:44; UTC

Uždarbis

Steris: Board Approves New $1B Shr Repurchase Program >STE

2026-05-11 20:43; UTC

Uždarbis

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

2026-05-11 20:32; UTC

Uždarbis

CleanSpark 2Q Loss/Shr $1.52 >CLSK

2026-05-11 20:32; UTC

Uždarbis

CleanSpark 2Q Rev $136.4M >CLSK

2026-05-11 20:30; UTC

Uždarbis

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Cont Ops EPS $2.24 >STE

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Rev $1.6B >STE

2026-05-11 20:30; UTC

Uždarbis

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Adj EPS $2.83 >STE

2026-05-11 20:22; UTC

Karštos akcijos

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

2026-05-11 19:37; UTC

Uždarbis

More Bad News at KKR's Private Credit Fund -- Barrons.com

2026-05-11 19:32; UTC

Rinkos pokalbiai

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

52.32% į viršų

12 mėnesių prognozė

Vidutinis 20 USD 52.32%

Aukščiausias 20 USD

Žemiausias 20 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

175 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.